Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reiterated by equities researchers at Oppenheimer in a research report issued on Thursday.

TEVA has been the subject of several other research reports. ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Evercore ISI set a $38.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, October 26th. Mizuho restated a “hold” rating and issued a $15.00 price target on shares of Teva Pharmaceutical Industries in a research note on Monday, October 30th. Finally, Wells Fargo & Co restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Saturday, November 25th. Ten investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have issued a buy rating to the company. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and a consensus target price of $21.15.

Teva Pharmaceutical Industries (TEVA) opened at $18.61 on Thursday. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $37.94. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $19,300.00, a price-to-earnings ratio of -1.15, a PEG ratio of 1.51 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. The firm had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. The company’s revenue was down 15.9% on a year-over-year basis. research analysts expect that Teva Pharmaceutical Industries will post 3.73 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of TEVA. Calton & Associates Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $108,000. Penserra Capital Management LLC bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $129,000. Fieldpoint Private Securities LLC bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $171,000. Global Financial Private Capital LLC bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $193,000. Finally, Wetherby Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $197,000. 51.99% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Given Hold Rating at Oppenheimer” was published by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2018/02/10/teva-pharmaceutical-industries-teva-given-hold-rating-at-oppenheimer.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.